Yongcan Wu

886 total citations
30 papers, 637 citations indexed

About

Yongcan Wu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Yongcan Wu has authored 30 papers receiving a total of 637 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 14 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Yongcan Wu's work include Heme Oxygenase-1 and Carbon Monoxide (13 papers), Inflammasome and immune disorders (7 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Yongcan Wu is often cited by papers focused on Heme Oxygenase-1 and Carbon Monoxide (13 papers), Inflammasome and immune disorders (7 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Yongcan Wu collaborates with scholars based in China, United States and Hong Kong. Yongcan Wu's co-authors include Demei Huang, Caixia Pei, Zhenxing Wang, Shihua Shi, Yilan Wang, Fei Wang, Zherui Shen, Yacong He, Xiaomin Wang and Xiaomin Wang and has published in prestigious journals such as Biochemical Pharmacology, Journal of Ethnopharmacology and European Journal of Pharmacology.

In The Last Decade

Yongcan Wu

29 papers receiving 622 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yongcan Wu China	15	362	218	117	98	65	30	637
Caixia Pei China	15	366 1.0×	216 1.0×	118 1.0×	98 1.0×	65 1.0×	33	644
Shihua Shi China	15	349 1.0×	202 0.9×	112 1.0×	81 0.8×	57 0.9×	36	629
Demei Huang China	16	378 1.0×	220 1.0×	121 1.0×	98 1.0×	70 1.1×	37	701
Zhenxing Wang China	16	412 1.1×	238 1.1×	134 1.1×	98 1.0×	66 1.0×	63	808
Zherui Shen China	13	251 0.7×	175 0.8×	97 0.8×	56 0.6×	35 0.5×	24	419
Fa Sun China	14	267 0.7×	205 0.9×	73 0.6×	18 0.2×	36 0.6×	49	610
Xiaoli Zeng China	15	189 0.5×	107 0.5×	58 0.5×	94 1.0×	147 2.3×	45	629
Beibei Gao China	16	250 0.7×	55 0.3×	96 0.8×	40 0.4×	76 1.2×	64	737
Shujing Chen China	13	186 0.5×	84 0.4×	25 0.2×	90 0.9×	69 1.1×	40	532
Wesley Gladwell United States	14	322 0.9×	153 0.7×	42 0.4×	83 0.8×	85 1.3×	20	689

Countries citing papers authored by Yongcan Wu

Since Specialization

Citations

This map shows the geographic impact of Yongcan Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongcan Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongcan Wu more than expected).

Fields of papers citing papers by Yongcan Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongcan Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongcan Wu. The network helps show where Yongcan Wu may publish in the future.

Co-authorship network of co-authors of Yongcan Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Yongcan Wu. A scholar is included among the top collaborators of Yongcan Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongcan Wu. Yongcan Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Yilan, Ying Liu, Caixia Pei, et al.. (2024). Notoginsenoside R1 treatment facilitated Nrf2 nuclear translocation to suppress ferroptosis via Keap1/Nrf2 signaling pathway to alleviated high-altitude myocardial injury. Biomedicine & Pharmacotherapy. 175. 116793–116793. 13 indexed citations

Liu, Junling, Caixia Pei, Zherui Shen, et al.. (2024). Preconditioning with Ginsenoside Rg3 mitigates cardiac injury induced by high-altitude hypobaric hypoxia exposure in mice by suppressing ferroptosis through inhibition of the RhoA/ROCK signaling pathway. Journal of Ethnopharmacology. 337(Pt 2). 118861–118861. 11 indexed citations

Pei, Caixia, Zherui Shen, Yongcan Wu, et al.. (2024). Eleutheroside B Pretreatment Attenuates Hypobaric Hypoxia‐Induced High‐Altitude Pulmonary Edema by Regulating Autophagic Flux via the AMPK/mTOR Pathway. Phytotherapy Research. 38(12). 5657–5671. 2 indexed citations

Huang, Demei, Zherui Shen, Caixia Pei, et al.. (2023). Sipeimine attenuates PM2.5-induced lung toxicity via suppression of NLRP3 inflammasome-mediated pyroptosis through activation of the PI3K/AKT pathway. Chemico-Biological Interactions. 376. 110448–110448. 14 indexed citations

Pei, Caixia, Yilan Wang, Zherui Shen, et al.. (2023). Notoginsenoside R1 protects against hypobaric hypoxia-induced high-altitude pulmonary edema by inhibiting apoptosis via ERK1/2-P90rsk-BAD ignaling pathway. European Journal of Pharmacology. 959. 176065–176065. 12 indexed citations

Huang, Demei, Caixia Pei, Zherui Shen, et al.. (2023). Rosavidin protects against PM2.5-induced lung toxicity via inhibition of NLRP3 inflammasome-mediated pyroptosis by activating the PI3K/AKT pathway. Biochemical Pharmacology. 213. 115623–115623. 8 indexed citations

Shi, Shihua, Demei Huang, Yongcan Wu, et al.. (2023). Salidroside pretreatment alleviates PM2.5 caused lung injury via inhibition of apoptosis and pyroptosis through regulating NLRP3 Inflammasome. Food and Chemical Toxicology. 177. 113858–113858. 17 indexed citations

Shen, Zherui, Demei Huang, Caixia Pei, et al.. (2023). Protective effects of Eleutheroside E against high-altitude pulmonary edema by inhibiting NLRP3 inflammasome-mediated pyroptosis. Biomedicine & Pharmacotherapy. 167. 115607–115607. 13 indexed citations

Shen, Zherui, Yilan Wang, Caixia Pei, et al.. (2023). Eleutheroside E from pre-treatment of Acanthopanax senticosus (Rupr.etMaxim.) Harms ameliorates high-altitude-induced heart injury by regulating NLRP3 inflammasome-mediated pyroptosis via NLRP3/caspase-1 pathway. International Immunopharmacology. 121. 110423–110423. 17 indexed citations

10.

Wang, Yilan, Zherui Shen, Demei Huang, et al.. (2022). Sipeimine ameliorates PM2.5-induced lung injury by inhibiting ferroptosis via the PI3K/Akt/Nrf2 pathway: A network pharmacology approach. Ecotoxicology and Environmental Safety. 239. 113615–113615. 53 indexed citations

11.

Huang, Demei, Shihua Shi, Yilan Wang, et al.. (2022). Astragaloside IV alleviates PM2.5-caused lung toxicity by inhibiting inflammasome‐mediated pyroptosis via NLRP3/caspase-1 axis inhibition in mice. Biomedicine & Pharmacotherapy. 150. 112978–112978. 28 indexed citations

12.

Wang, Xiaomin, Shuiqin Li, Yongcan Wu, et al.. (2022). Effect of omega-3 fatty acids on TH1/TH2 polarization in individuals with high exposure to particulate matter ≤ 2.5 μm (PM2.5): a randomized, double-blind, placebo-controlled clinical study. Trials. 23(1). 179–179. 1 indexed citations

13.

Shi, Shihua, Fei Wang, Huan Yao, et al.. (2022). Oral Chinese Herbal Medicine on Immune Responses During Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Frontiers in Medicine. 8. 685734–685734. 17 indexed citations

14.

Wang, Xiaoming, Yilan Wang, Demei Huang, et al.. (2022). Astragaloside IV regulates the ferroptosis signaling pathway via the Nrf2/SLC7A11/GPX4 axis to inhibit PM2.5-mediated lung injury in mice. International Immunopharmacology. 112. 109186–109186. 106 indexed citations

15.

Pei, Caixia, Fei Wang, Demei Huang, et al.. (2021). Astragaloside IV Protects from PM2.5-Induced Lung Injury by Regulating Autophagy via Inhibition of PI3K/Akt/mTOR Signaling in vivo and in vitro. Journal of Inflammation Research. Volume 14. 4707–4721. 45 indexed citations

16.

Wu, Yongcan, Demei Huang, Xiaomin Wang, et al.. (2021). Suppression of NLRP3 inflammasome by Platycodin D via the TLR4/MyD88/NF-κB pathway contributes to attenuation of lipopolysaccharide induced acute lung injury in rats. International Immunopharmacology. 96. 107621–107621. 34 indexed citations

17.

Wang, Zhenxing, Yongcan Wu, Caixia Pei, et al.. (2021). Astragaloside IV pre-treatment attenuates PM2.5-induced lung injury in rats: Impact on autophagy, apoptosis and inflammation. Phytomedicine. 96. 153912–153912. 38 indexed citations

18.

Wu, Yongcan, et al.. (2020). Effect of probiotics, prebiotics and synbiotics for chronic bronchitis or chronic obstructive pulmonary disease. Medicine. 99(45). e23045–e23045. 8 indexed citations

19.

Wu, Yongcan, Wei Xiao, Caixia Pei, et al.. (2020). Astragaloside IV alleviates PM2.5-induced lung injury in rats by modulating TLR4/MyD88/NF-κB signalling pathway. International Immunopharmacology. 91. 107290–107290. 38 indexed citations

20.

Wu, Yongcan, Caixia Pei, Xiaomin Wang, et al.. (2020). Effect of probiotics on nasal and intestinal microbiota in people with high exposure to particulate matter ≤ 2.5 μm (PM2.5): a randomized, double-blind, placebo-controlled clinical study. Trials. 21(1). 850–850. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact